Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18596600 | 1.00 | PTGS1 (0.43) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL22267884 | 1.00 | PTGS1 (0.43) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL24343716 | 0.90 | PTGS1 (0.40) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL22668670 | 0.88 | PTGS1 (0.37) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL20670908 | 0.87 | PTGS1 (0.46) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL2560238 | 0.87 | PTGS1 (0.49) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL22267879 | 0.87 | PTGS1 (0.46) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL16069853 | 0.87 | PTGS1 (0.46) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL2560233 | 0.87 | PTGS1 (0.49) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 | |
| SCHEMBL12285559 | 0.87 | PTGS1 (0.49) | PTGS1PTGS2CASP1MGLLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767365-B2 | BCMA antibodies and use of same to treat cancer and immunological disorders | SEAGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-20220025062-A1 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | SEAGEN INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11230610-B2 | Bivalent antibodies masked by coiled coils | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11078291-B2 | BCMA antibodies and use of same to treat cancer and immunological disorders | SEAGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11027021-B2 | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors | SEAGEN INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190352428-A1 | BIVALENT ANTIBODIES MASKED BY COILED COILS | SEATTLE GENETICS, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-10391181-B2 | Cyclodextrin and antibody-drug conjugate formulations | SEATTLE GENETICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190194338-A1 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | SEATTLE GENETICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190117787-A1 | COMBINATIONS OF CD33 ANTIBODY DRUG CONJUGATES WITH HYPOMETHYLATING AGENTS | SEATTLE GENETICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190076549-A1 | COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH BCL-2 INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9987374-B2 | Cyclodextrin and antibody-drug conjugate formulations | SEATTLE GENETICS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170232112-A1 | CYCLODEXTRIN AND ANTIBODY-DRUG CONJUGATE FORMULATIONS | SEATTLE GENETICS, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233484-A1 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | SEATTLE GENETICS, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-9610361-B2 | Cyclodextrin and antibody-drug conjugate formulations | SEATTLE GENETICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9587019-B2 | CD33 antibodies and use of same to treat cancer | SEATTLE GENETICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194338-A1 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | CD47, IGSF11, BCR | PTGS1 4167/4885PTGS2 4409/4885CASP1 4213/4885 |
| US-11078291-B2 | BCMA antibodies and use of same to treat cancer and immunological disorders | CD47, IGSF11, BCR | PTGS1 4167/4885PTGS2 4409/4885CASP1 4213/4885 |
| US-20190117787-A1 | COMBINATIONS OF CD33 ANTIBODY DRUG CONJUGATES WITH HYPOMETHYLATING AGENTS | ENTPD3, NEU3, CD47 | PTGS1 4622/4885PTGS2 4410/4885CASP1 4074/4885 |
| US-20190076549-A1 | COMBINATIONS OF PBD-BASED ANTIBODY DRUG CONJUGATES WITH BCL-2 INHIBITORS | BCL3, BAK1, MCL1 | PTGS1 4291/4885PTGS2 2627/4885CASP1 1422/4885 |
| US-20220025062-A1 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | CD47, IGSF11, BCR | PTGS1 4167/4885PTGS2 4409/4885CASP1 4213/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | PTGS1 2084/4885PTGS2 2219/4885CASP1 3681/4885 |
| US-10391181-B2 | Cyclodextrin and antibody-drug conjugate formulations | CDR2, GABRA6, GABRA4 | PTGS1 4682/4885PTGS2 4741/4885CASP1 3289/4885 |
| US-20170232112-A1 | CYCLODEXTRIN AND ANTIBODY-DRUG CONJUGATE FORMULATIONS | CDR2, GABRA6, GABRA4 | PTGS1 4682/4885PTGS2 4741/4885CASP1 3289/4885 |
| US-11767365-B2 | BCMA antibodies and use of same to treat cancer and immunological disorders | CD47, IGSF11, BCR | PTGS1 4167/4885PTGS2 4409/4885CASP1 4213/4885 |
| US-11027021-B2 | Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors | BCL3, BAK1, MCL1 | PTGS1 4291/4885PTGS2 2627/4885CASP1 1422/4885 |
| US-20190352428-A1 | BIVALENT ANTIBODIES MASKED BY COILED COILS | COIL, CRYAB, UACA | PTGS1 4324/4885PTGS2 3574/4885CASP1 2029/4885 |
| US-11230610-B2 | Bivalent antibodies masked by coiled coils | COIL, CRYAB, UACA | PTGS1 4324/4885PTGS2 3574/4885CASP1 2029/4885 |
| US-20170233484-A1 | BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS | CD47, IGSF11, BCR | PTGS1 4167/4885PTGS2 4409/4885CASP1 4213/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | PTGS1 2084/4885PTGS2 2219/4885CASP1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.